EUVIMEDAvasta EUVIMED
Crossref

Transition of average drug‐to‐antibody ratio of trastuzumab deruxtecan in systemic circulation in monkeys using a hybrid affinity capture liquid chromatography‐tandem mass spectrometry

Hiromi Habara iD, Hiromi Okamoto, Yoko Nagai, Masataka Oitate iD, Hideo Takakusa, Nobuaki Watanabe

Biopharmaceutics & Drug Disposition · 2023

DOI: 10.1002/bdd.2371 ↗

At a glance

Journal article in Biopharmaceutics & Drug Disposition, 2023. Written by Hiromi Habara and 5 co-authors. Institution: Drug Metabolism & Pharmacokinetics Research Laboratories, Daiichi Sankyo Co., Ltd., Tokyo, Japan. Major MEDLINE topics: Trastuzumab, Immunoconjugates, Camptothecin, Antibodies, Monoclonal, Humanized. Cited 6 times so far (Crossref); 18 references.

AbstraktSubjectsBibliograafilised andmedCiteRelated studies

Abstract (original language)

Trastuzumab deruxtecan (T‐DXd, DS‐8201a) is an antibody–drug conjugate, comprising an anti‐HER2 antibody at a drug‐to‐antibody ratio of 7–8 with the topoisomerase I inhibitor DXd. In this study, the concentrations of antibody‐conjugated DXd and total antibody were determined and observed to decrease over time following intravenous administration of T‐DXd to monkeys. The drug‐to‐antibody ratio of T‐DXd also decreased in a time‐dependent manner, which reached approximately 2.5 in 21 days after administration. It was suggested that antibody‐conjugated DXd of T‐DXd was relatively stable in vivo compared with that of other reported antibody–drug conjugates.

Subjects

MeSH terms (MEDLINE)

TrastuzumabImmunoconjugatesCamptothecinAntibodies, Monoclonal, HumanizedAnimalsTandem Mass SpectrometryMacaca fascicularisChromatography, LiquidMaleTopoisomerase I InhibitorsFemale

Author keywords

antibody-conjugated DXdantibody-drug conjugate (ADC)average drug-to-antibody ratio (average DAR)total antibodytrastuzumab deruxtecan (T-DXd, DS-8201a)

Substances

TrastuzumabImmunoconjugatestrastuzumab deruxtecanCamptothecinTopoisomerase I InhibitorsAntibodies, Monoclonal, Humanized

Authors and institutions

  • Drug Metabolism & Pharmacokinetics Research Laboratories, Daiichi Sankyo Co., Ltd., Tokyo, Japan.

ORCID profiles: Hiromi Habara, Masataka Oitate

Cite

APA

Habara, H., Okamoto, H., Nagai, Y., Oitate, M., Takakusa, H., & Watanabe, N. (2023). Transition of average drug‐to‐antibody ratio of trastuzumab deruxtecan in systemic circulation in monkeys using a hybrid affinity capture liquid chromatography‐tandem mass spectrometry. Biopharmaceutics & Drug Disposition. https://doi.org/10.1002/bdd.2371

Vancouver

Habara H, Okamoto H, Nagai Y, Oitate M, Takakusa H, Watanabe N. Transition of average drug‐to‐antibody ratio of trastuzumab deruxtecan in systemic circulation in monkeys using a hybrid affinity capture liquid chromatography‐tandem mass spectrometry. Biopharmaceutics & Drug Disposition. 2023. doi:10.1002/bdd.2371

BibTeX
@article{Habara2023,
  author = {Habara, Hiromi and Okamoto, Hiromi and Nagai, Yoko and Oitate, Masataka and Takakusa, Hideo and Watanabe, Nobuaki},
  title = {Transition of average drug‐to‐antibody ratio of trastuzumab deruxtecan in systemic circulation in monkeys using a hybrid affinity capture liquid chromatography‐tandem mass spectrometry},
  journal = {Biopharmaceutics & Drug Disposition},
  year = {2023},
  doi = {10.1002/bdd.2371}
}
Start for free →